CELZ - Creative Medical Technology rises ~9% on FDA nod to start cell therapy trial in diabetes
- Creative Medical Technology ( NASDAQ: CELZ ) on Thursday said the U.S. FDA had cleared the company's investigational new drug application to initiate a clinical trial with its AlloStem cell therapy for type 1 diabetes.
- Shares of the micro-cap biotech gained 9.1% to $0.44 in morning trading.
- The primary objective of the trial will be to assess AlloStem in patients with newly diagnosed type 1 diabetes.
- According to CELZ, AlloStem harnesses perinatal tissue derived cells.
- Patient recruitment for the trial is anticipated to start in Q1 2023.
For further details see:
Creative Medical Technology rises ~9% on FDA nod to start cell therapy trial in diabetes